This therapeutic concept targets the restoration of circular RNA (circRNA) function in neurodegenerative diseases. CircRNAs are abundant in the brain, highly stable, and play critical roles in synaptic function, protein translation, and gene regulation. Their dysregulation contributes to amyloid metabolism, tau pathology, alpha-synuclein regulation, and synaptic dysfunction across Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
CircRNAs are covalently closed loop structures lacking 5' caps and 3' poly(A) tails, conferring high stability in brain tissue. In neurodegeneration:
The therapeutic approach restores circRNA function through:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | First-in-class mechanism targeting circRNA biogenesis and function |
| Mechanistic Rationale | 8 | Strong evidence from human brain studies showing circRNA dysregulation across AD, PD, ALS |
| Root-Cause Coverage | 7 | Addresses upstream RNA dysregulation that contributes to protein aggregation |
| Delivery Feasibility | 5 | CNS delivery challenging but ASO and AAV technologies exist; LNP-mRNA delivery emerging |
| Safety Plausibility | 6 | Gene-specific targeting reduces off-target risk; circRNA mimics are non-coding |
| Combinability | 8 | Can combine with ASOs, small molecules, and standard-of-care therapies |
| Biomarker Availability | 7 | CircRNAs themselves serve as biomarkers; can measure in CSF and blood |
| De-risking Path | 6 | iPSC-derived neurons and animal models available; established ASO development platform |
| Multi-disease Potential | 8 | CircRNA dysregulation common across AD, PD, ALS, and FTD |
| Patient Impact | 7 | Could be disease-modifying by restoring endogenous neuroprotective mechanisms |
Total Score: 71/100
| Disease | Priority | Rationale |
|---|---|---|
| Alzheimer's Disease | High | Strong circRNA dysregulation evidence; links to amyloid and tau |
| Parkinson's Disease | High | circSNCA directly regulates alpha-synuclein |
| ALS | Medium | TDP-43circRNA interplay; C9orf72 connections |
| FTD | Medium | TDP-43 pathology overlaps with ALS |
| Company/Group | Approach | Stage |
|---|---|---|
| Ionis Pharmaceuticals | ASO platform | Preclinical |
| Avid Radiopharmaceuticals | circRNA biomarkers | Diagnostic |
| Academic consortia | circRNA atlases | Research |
| Risk | Mitigation |
|---|---|
| Delivery to CNS | Use intrathecal or AAV9-mediated delivery |
| Off-target effects | Engineer high-specificity ASOs |
| Variable circRNA expression | Patient stratification by biomarker signature |
| Immune response to viral vectors | Use non-immunogenic delivery systems |
[^
| Scenario | Probability | Cost Impact | Timeline Impact |
|---|---|---|---|
| Best case | 15% | $53.5M | 48 months |
| Base case | 50% | $65M | 54 months |
| Conservative | 25% | $88.5M | 66 months |
| Failure | 10% | $15M (Phase 1) | 18 months |
Circular RNAs in Alzheimer's Disease: From Bench to Bedside (2023). 2023. ↩︎
Synaptic Circular RNAs: Implications for Neurodegenerative Diseases (2023). 2023. ↩︎
circSNCA-mediated Pathogenesis in Parkinson's Disease (2023). 2023. ↩︎
TDP-43 and Circular RNAs in Amyotrophic Lateral Sclerosis (2024). 2024. ↩︎